Oncolytic Viral Therapy Market - 2025-2033
Oncolytic Viral Therapy Market reached US$ 24.48 Million in 2024 and is expected to reach US$ 164.51 Million by 2033, growing with a CAGR of 23.80% during the forecast period 2026-2033.
The Oncolytic Viral Therapy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Oncolytic Viral Therapy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Virus Type
Both primary and secondary data sources have been used in the global Oncolytic Viral Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Oncolytic Viral Therapy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Oncolytic Viral Therapy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Virus Type
- Adenoviruses*
- Herpes Simplex Virus
- Maraba Virus
- Measles
- Newcastle Disease Virus
- Picornavirus
- Reovirus
- Vaccinia Virus
- Vesicular Stomatitis Virus
- Others
- Melanoma*
- Breast Cancer
- Prostate Cancer
- Ovarian Cancer
- Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Head and Neck Cancer
- Others
- Intratumoral Injection*
- Intravenous Infusion
- Intracavitary Injection
- Others
- Hospitals*
- Oncology Centers
- Ambulatory Surgical Centers
- Cancer Research Institutes
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Oncolytic Viral Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY VIRUS TYPE
4.1. Snippet by Application
4.2. Snippet by Mode of Administration
4.3. Snippet by End-User
4.4. Snippet by Region
5. DYNAMICS
5.1. Impacting Factors
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Cancer and Unmet Treatment Needs
5.1.1.2. Personalization & Biomarker-Driven Development
5.1.1.3. Rising Advancements in Oncolytic Viral Therapy
5.1.2. Restraints
5.1.2.1. High Costs Associated with Oncolytic Viral Therapy
5.1.2.2. Safety and Regulatory Stringency
5.1.3. Opportunity
5.1.3.1. Expansion into Hard-to-Treat, Immunologically Cold Tumors
5.1.3.2. Next-Generation Engineered Viruses as Therapeutic Platforms
5.1.4. Impact Analysis
6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
6.1. Market Leaders and Pioneers
6.1.1. Emerging Pioneers and Prominent Players
6.1.2. Established Leaders with the Largest Marketing Brand
6.1.3. Market Leaders with Established Products
6.2. Latest Developments and Breakthroughs
6.3. Regulatory and Reimbursement Landscape
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. South America
6.3.5. Middle East & Africa
6.4. Porter’s Five Forces Analysis
6.5. Supply Chain Analysis
6.6. Patent Analysis
6.7. SWOT Analysis
6.8. Unmet Needs and Gaps
6.9. Recommended Strategies for Market Entry and Expansion
6.10. Pricing Analysis and Price Dynamics
7. ONCOLYTIC VIRAL THERAPY MARKET, BY VIRUS TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
7.1.2. Market Attractiveness Index, By Virus Type
7.2. Adenoviruses*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Herpes Simplex Virus
7.4. Maraba Virus
7.5. Measles
7.6. Newcastle Disease Virus
7.7. Picornavirus
7.8. Reovirus
7.9. Vaccinia Virus
7.10. Vesicular Stomatitis Virus
7.11. Others
8. ONCOLYTIC VIRAL THERAPY MARKET, BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Melanoma*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Breast Cancer
8.4. Prostate Cancer
8.5. Ovarian Cancer
8.6. Lung Cancer
8.7. Pancreatic Cancer
8.8. Colorectal Cancer
8.9. Head and Neck Cancer
8.10. Others
9. ONCOLYTIC VIRAL THERAPY MARKET, BY MODE OF ADMINISTRATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
9.1.2. Market Attractiveness Index, By Mode of Administration
9.2. Intratumoral Injection*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous Infusion
9.4. Intracavitary Injection
9.5. Others
10. ONCOLYTIC VIRAL THERAPY MARKET, BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Oncology Centers
10.4. Ambulatory Surgical Centers
10.5. Cancer Research Institutes
10.6. Others
11. ONCOLYTIC VIRAL THERAPY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
12. INTRODUCTION
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.1. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. U.S.
12.2.7.2. Canada
12.2.7.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Germany
12.3.7.2. UK
12.3.7.3. France
12.3.7.4. Spain
12.3.7.5. Italy
12.3.7.6. Rest of Europe
12.4. Asia-Pacific
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.7.1. China
12.4.7.2. India
12.4.7.3. Japan
12.4.7.4. South Korea
12.4.7.5. Rest of Asia-Pacific
12.5. South America
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.7.1. Brazil
12.5.7.2. Argentina
12.5.7.3. Rest of South America
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
14. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
14.1. Market Share Analysis and Positioning Matrix
14.2. Strategic Partnerships, Mergers & Acquisitions
14.3. Key Developments in Product Portfolios and Innovations
14.4. Company Benchmarking
15. COMPANY PROFILES
15.1. Amgen, Inc.*
15.1.1. Company Overview
15.1.2. Product Portfolio
15.1.2.1. Product Description
15.1.2.2. Product Key Performance Indicators (KPIs)
16. FINANCIAL OVERVIEW
16.1. Company Revenue
16.1.1. Geographical Revenue Shares
16.1.1.1. Revenue Forecasts
16.1.2. Key Developments
16.1.2.1. Mergers & Acquisitions
16.1.2.2. Key Product Development Activities
16.1.2.3. Regulatory Approvals, etc.
16.1.3. SWOT Analysis
16.2. Daiichi Sankyo Co., Ltd.
16.3. Lokon Pharma AB
16.4. Virogin Biotech Canada Ltd
16.5. KaliVir Immunotherapeutics, Inc.
16.6. Transgene SA
16.7. Vyriad, Inc.
16.8. Coastar Theapeutics Inc.
16.9. IconOVir Bio, Inc.
16.10. Calidi Biotherapeutics, Inc. (LIST NOT EXHAUSTIVE*)
17. ASSUMPTIONS AND RESEARCH METHODOLOGY
17.1. Data Collection Methods
17.2. Data Triangulation
17.3. Forecasting Techniques
17.4. Data Verification and Validation
18. APPENDIX
18.1. About Us and Services
18.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY VIRUS TYPE
4.1. Snippet by Application
4.2. Snippet by Mode of Administration
4.3. Snippet by End-User
4.4. Snippet by Region
5. DYNAMICS
5.1. Impacting Factors
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Cancer and Unmet Treatment Needs
5.1.1.2. Personalization & Biomarker-Driven Development
5.1.1.3. Rising Advancements in Oncolytic Viral Therapy
5.1.2. Restraints
5.1.2.1. High Costs Associated with Oncolytic Viral Therapy
5.1.2.2. Safety and Regulatory Stringency
5.1.3. Opportunity
5.1.3.1. Expansion into Hard-to-Treat, Immunologically Cold Tumors
5.1.3.2. Next-Generation Engineered Viruses as Therapeutic Platforms
5.1.4. Impact Analysis
6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
6.1. Market Leaders and Pioneers
6.1.1. Emerging Pioneers and Prominent Players
6.1.2. Established Leaders with the Largest Marketing Brand
6.1.3. Market Leaders with Established Products
6.2. Latest Developments and Breakthroughs
6.3. Regulatory and Reimbursement Landscape
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. South America
6.3.5. Middle East & Africa
6.4. Porter’s Five Forces Analysis
6.5. Supply Chain Analysis
6.6. Patent Analysis
6.7. SWOT Analysis
6.8. Unmet Needs and Gaps
6.9. Recommended Strategies for Market Entry and Expansion
6.10. Pricing Analysis and Price Dynamics
7. ONCOLYTIC VIRAL THERAPY MARKET, BY VIRUS TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
7.1.2. Market Attractiveness Index, By Virus Type
7.2. Adenoviruses*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Herpes Simplex Virus
7.4. Maraba Virus
7.5. Measles
7.6. Newcastle Disease Virus
7.7. Picornavirus
7.8. Reovirus
7.9. Vaccinia Virus
7.10. Vesicular Stomatitis Virus
7.11. Others
8. ONCOLYTIC VIRAL THERAPY MARKET, BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Melanoma*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Breast Cancer
8.4. Prostate Cancer
8.5. Ovarian Cancer
8.6. Lung Cancer
8.7. Pancreatic Cancer
8.8. Colorectal Cancer
8.9. Head and Neck Cancer
8.10. Others
9. ONCOLYTIC VIRAL THERAPY MARKET, BY MODE OF ADMINISTRATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
9.1.2. Market Attractiveness Index, By Mode of Administration
9.2. Intratumoral Injection*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous Infusion
9.4. Intracavitary Injection
9.5. Others
10. ONCOLYTIC VIRAL THERAPY MARKET, BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Oncology Centers
10.4. Ambulatory Surgical Centers
10.5. Cancer Research Institutes
10.6. Others
11. ONCOLYTIC VIRAL THERAPY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
12. INTRODUCTION
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.1. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. U.S.
12.2.7.2. Canada
12.2.7.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Germany
12.3.7.2. UK
12.3.7.3. France
12.3.7.4. Spain
12.3.7.5. Italy
12.3.7.6. Rest of Europe
12.4. Asia-Pacific
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.7.1. China
12.4.7.2. India
12.4.7.3. Japan
12.4.7.4. South Korea
12.4.7.5. Rest of Asia-Pacific
12.5. South America
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.7.1. Brazil
12.5.7.2. Argentina
12.5.7.3. Rest of South America
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
14. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
14.1. Market Share Analysis and Positioning Matrix
14.2. Strategic Partnerships, Mergers & Acquisitions
14.3. Key Developments in Product Portfolios and Innovations
14.4. Company Benchmarking
15. COMPANY PROFILES
15.1. Amgen, Inc.*
15.1.1. Company Overview
15.1.2. Product Portfolio
15.1.2.1. Product Description
15.1.2.2. Product Key Performance Indicators (KPIs)
16. FINANCIAL OVERVIEW
16.1. Company Revenue
16.1.1. Geographical Revenue Shares
16.1.1.1. Revenue Forecasts
16.1.2. Key Developments
16.1.2.1. Mergers & Acquisitions
16.1.2.2. Key Product Development Activities
16.1.2.3. Regulatory Approvals, etc.
16.1.3. SWOT Analysis
16.2. Daiichi Sankyo Co., Ltd.
16.3. Lokon Pharma AB
16.4. Virogin Biotech Canada Ltd
16.5. KaliVir Immunotherapeutics, Inc.
16.6. Transgene SA
16.7. Vyriad, Inc.
16.8. Coastar Theapeutics Inc.
16.9. IconOVir Bio, Inc.
16.10. Calidi Biotherapeutics, Inc. (LIST NOT EXHAUSTIVE*)
17. ASSUMPTIONS AND RESEARCH METHODOLOGY
17.1. Data Collection Methods
17.2. Data Triangulation
17.3. Forecasting Techniques
17.4. Data Verification and Validation
18. APPENDIX
18.1. About Us and Services
18.2. Contact Us
